Search Clinical Trials in the EU

Duration

Visits

Phase

Intake methods

Partially Remote

Drugs

Locations

Clinical Specialty

761-780 of 998 trials

Vosoritide for Growth Issues in Children

We are studying a new treatment called vosoritide for children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome who haven't responded well to standard growth hormone therapy. The goal is to see if it helps improve their growth and is safe to use.

Turner SyndromeShort Stature Homeobox Gene MutationNoonan Syndrome1-2 yearsEfficacy phase (II)Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteEndocrinologyPediatrics

Chickenpox Vaccine Safety Study for Young Children

We are evaluating the safety of a new chickenpox vaccine for healthy children aged 12 to 15 months. This study compares it with an existing vaccine when given with other routine immunizations.

Chickenpox6-12 monthsConfirmation phase (III)No Placebo Standard Medicines Cost Reimbursement Partially RemoteInfectious DiseasesPediatrics

Chickenpox Vaccine Study for Children Aged 12 to 15 Months

We are evaluating a new chickenpox vaccine to see how well it works and its safety compared to the standard Varivax vaccine in healthy children. This study aims to ensure that the new vaccine provides a strong immune response.

Chickenpox6-12 monthsConfirmation phase (III)≤5 visits No Placebo Standard Medicines Cost Reimbursement Partially RemoteInfectious DiseasesPediatrics

Small Cell Lung Cancer: Sacituzumab Govitecan vs. Standard Care

We are studying a new treatment called sacituzumab govitecan for patients with previously treated extensive stage small cell lung cancer. The goal is to see if it works better and is safer than current standard treatments.

Extensive Stage Small Cell Lung CancerConfirmation phase (III)≤5 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteOncology

Alpha-1 Antitrypsin Deficiency: Prolastin® Self-Infusion Therapy

We are studying the safety of a self-infusion therapy with Prolastin® for patients with severe alpha-1-antitrypsin deficiency. The trial also looks at quality of life and patient satisfaction with this treatment.

Alpha-1 Antitrypsin Deficiency3-6 monthsConfirmation phase (III)>20 visits No Placebo Standard Medicines Partially RemoteInternal MedicinePulmonology

Posttraumatic Headache: Botulinum Toxin A Study

We are investigating whether botulinum toxin A can safely reduce the number of headache days for individuals with posttraumatic headaches. The study also looks at biological markers to see if they can predict treatment success.

Post-Traumatic Headache3-6 monthsConfirmation phase (III)≤5 visits Standard Medicines Cost Reimbursement Partially RemoteInternal MedicineNeurology

Chronic Lung Disease in Premature Babies: OHB-607 Study

We are testing a new drug to see if it helps reduce lung disease in extremely premature infants compared to standard care. The study aims to improve their overall health and development.

Chronic Lung Disease6-12 monthsEfficacy phase (II)≤5 visits No Placebo Standard Medicines Cost Reimbursement Partially RemotePediatricsPulmonology

Atrial Fibrillation After CABG: Anticoagulant Study

We are studying whether adding anticoagulant medications helps prevent blood clots in patients with new-onset atrial fibrillation after heart surgery. This trial aims to ensure safety and effectiveness in managing this condition.

Atrial FibrillationNew-Onset Post-Operative Atrial Fibrillation after CABG6-12 monthsMonitoring phase (IV)No Placebo Investigational Medicines Partially RemoteCardiologyInternal Medicine

Iptacopan for Pediatric Patients with PNH

We are studying the safety and tolerability of iptacopan in children with PNH. The trial will also evaluate its effects on hemoglobin levels and the need for blood transfusions.

Paroxysmal Nocturnal Hemoglobinuria (PNH)6-12 monthsConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteHematologyInternal Medicine

Drug-Resistant Epilepsy: Rapamycin Study

We are investigating whether rapamycin is safe and effective for people with drug-resistant epilepsy due to tuberous sclerosis complex. The study also examines its effects on related neuropsychiatric disorders and tumors.

Tuberous Sclerosis Complex3-6 monthsConfirmation phase (III)>20 visits Post-Trial Drug Access Standard Medicines Partially RemoteInternal MedicineNeurology

Hidradenitis Suppurativa: Brensocatib Study

We are testing a new medication, brensocatib, for adults with moderate to severe hidradenitis suppurativa. The study aims to see if it is more effective than a placebo in improving symptoms.

Hidradenitis Suppurativa1-2 yearsEfficacy phase (II)16-20 visits Investigational Medicines Cost Reimbursement Partially RemoteDermatology

Rheumatoid Arthritis: IMVT-1402 Treatment Study

We are evaluating a new treatment for adults with difficult-to-treat rheumatoid arthritis. The study aims to see if it helps improve symptoms compared to a placebo.

ACPA-Positive Rheumatoid Arthritis6-12 monthsEfficacy phase (II)>20 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteRheumatology

Cardiac Arrest: Ketamine vs. Propofol Sedation

We are studying whether ketamine sedation can better protect the brain and improve survival compared to propofol in patients resuscitated from cardiac arrest. This trial looks at outcomes at discharge and 180 days later.

Out-of-Hospital Cardiac Arrest1-2 yearsConfirmation phase (III)Monitoring phase (IV)No Placebo Standard Medicines Partially RemoteCardiologyNeurology

Crohn's Disease: Adalimumab Treatment Study

We are comparing a new approach using adalimumab for newly diagnosed Crohn's disease patients against standard treatments. The goal is to see which method is safer and more effective in the long run.

Crohn's Disease3-6 monthsMonitoring phase (IV)≤5 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteGastroenterologyInternal Medicine

Efgartigimod for Early Treatment of Generalized Myasthenia Gravis

We are studying whether efgartigimod can improve daily activities and quality of life for patients with generalized myasthenia gravis and specific antibodies. This trial will help us understand its effectiveness and tolerability as an early treatment option.

Generalized Myasthenia Gravis6-12 monthsMonitoring phase (IV)11-15 visits No Placebo Standard Medicines Partially RemoteNeurology

Multiple Myeloma: Belantamab Mafodotin vs. Daratumumab

We are studying a new treatment combination for people with newly diagnosed multiple myeloma who cannot have stem cell transplants. The goal is to see if it works better and is safer than the current standard treatment.

Multiple MyelomaConfirmation phase (III)11-15 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteHematologyOncology

Chronic Myeloid Leukemia: Asciminib Treatment Study

We are studying Asciminib for patients with Chronic Myeloid Leukemia who have the T315I mutation and have not responded to ponatinib. The trial aims to see how well it works and how safe it is.

Chronic Myeloid Leukemia>2 yearsEfficacy phase (II)≤5 visits Post-Trial Drug Access No Placebo Standard Medicines Partially RemoteOncology

Retinitis Pigmentosa: GS030 Gene Therapy Study

We are evaluating a new gene therapy to see if it is safe and can improve vision in people with retinitis pigmentosa. Participants will receive a single injection and undergo light stimulation to assess potential benefits.

Retinitis Pigmentosa1-2 yearsSafety phase (I)Efficacy phase (II)>20 visits Post-Trial Drug Access No Placebo Investigational Medicines Partially RemoteOphthalmology

HIV-1 Infection: ART with Long-Acting Antibodies

We are studying whether adding long-acting HIV-specific antibodies to standard treatment can help people with primary HIV-1 infection achieve better control after stopping therapy. This trial will also look at how well participants tolerate the treatment.

HIV-1 Infection>2 yearsEfficacy phase (II)16-20 visits Investigational Medicines Partially RemoteInfectious Diseases

Advanced Breast Cancer: Inavolisib Treatment Study

We are studying a new treatment combining inavolisib with standard medications for patients with advanced hormone receptor-positive breast cancer. The goal is to see if this combination works better than a placebo in managing the disease.

Advanced Breast Cancer>2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Partially RemoteOncology

Search Clinical Trials in the European Union